NCT05047731Completed
Antihypertensive Deprescribing in Long-term Care
Antihypertensive Deprescribing in Long-term Care: A Randomized Controlled Trial (OptimizeBP)
Source: ClinicalTrials.gov · Last updated 8 Jan 2026
Brief summary (registry, in English)
Frail older adults are commonly prescribed blood pressure medication, yet it is unclear if blood pressure medication is actually beneficial for them. Observational studies in this population suggest blood pressure medication has limited benefit and may even be harmful, including an increased risk for falls and cognitive impairment. Randomized controlled trials are needed to confirm this. This study is a randomized controlled trial of blood pressure medication deprescribing, amongst long-term care residents with systolic blood pressure lower than 135 mmHg. In the intervention group, with physician consent, the facility pharmacist or nurse practitioner will continually reduce antihypertensives provided an upper systolic threshold of 145 mmHg is not exceeded. The control group will receive usual care. The hypothesis is that avoiding unnecessarily low systolic blood pressure is beneficial in a frail, end-of-life population.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 522 (actual)
- First submitted
- 8 Sept 2021
- Start date
- 20 Sept 2021
- Primary completion date
- 30 Nov 2025
- Lead sponsor
- University of Alberta
- Diseases
- High blood pressure
- NCT number
- NCT05047731
What you commit to
- Study type: Interventional
- Participants enrolled: 522
- From 20 Sept 2021 to the primary completion date, 30 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- ≥2 community dx of congestive heart failure, ≥1 dx of in hospital congestive heart failure, ≥1 dx of emergency visit of congestive heart failure, dx of congestive heart failure in RAI-MDS 2.0, or prescription of furosemide in the last 15 days.
Lab values
- The resident's only antihypertensive prescribed is a calcium channel blocker and the resident has ≥1 health system encounters with a diagnosis of angina.
Other
- The resident's only antihypertensive prescribed is a beta blocker.
- The resident's only antihypertensive prescribed is an alpha blocker.
- Admitted to the hospital at the time of randomization; or opted out of the trial by the resident, their family, their physician, or the facility.
Who the study is looking for
- ≥2 diagnoses (dx) of hypertension from either a community practitioner or/and from a hospital admission.
- On ≥1 oral antihypertensive medication (requires a dispensation in the preceeding 15 days).
- Average recorded systolic BP of \<135 mmHg.
Age in the registry: 70 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Multiple long-term care facilities Coordinator of this site? Confirm its status | Multiple Locations | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.